

Item 8.01 Other Events.

On August 19, 2014, Emergent BioSolutions Inc. issued a press release announcing that it has entered into an agreement with MorphoSys AG for the joint development and commercialization of ES414, a bi-specific antibody targeting prostate cancer developed by Emergent using its proprietary ADAPTIR™ platform.

A copy of the press release is attached as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99 Press Release issued by Emergent BioSolutions Inc. on August 19, 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 19, 2014 EMERGENT BIOSOLUTIONS INC.

/s/ A.B. Cruz

By: A.B. Cruz III
Executive Vice President & General Counsel